



Age/Gender : 32 Y 5 M 16 D/F
UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963 Collected : 27/Nov/2023 10:19AM

Received : 27/Nov/2023 10:55AM Reported : 27/Nov/2023 12:52PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

PERIPHERAL SMEAR , WHOLE BLOOD EDTA

Page 1 of 12







: Mrs.RUPAL KUMARI Patient Name

Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963

Collected : 27/Nov/2023 10:19AM Received : 27/Nov/2023 10:55AM

Reported : 27/Nov/2023 12:52PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

DELYNTHER OF THE HINT OF THE H					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

Status

HAEMOGLOBIN	9.6	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	31.40	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.38	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	71.7	fL	83-101	Calculated
MCH	22	pg	27-32	Calculated
MCHC	30.7	g/dL	31.5-34.5	Calculated
R.D.W	16.6	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,290	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)	<u> </u>		
NEUTROPHILS	57.1	%	40-80	Electrical Impedance
LYMPHOCYTES	32.2	%	20-40	Electrical Impedance
EOSINOPHILS	4.2	%	1-6	Electrical Impedance
MONOCYTES	6	%	2-10	Electrical Impedance
BASOPHILS	0.5	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3020.59	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1703.38	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	222.18	Cells/cu.mm	20-500	Calculated
MONOCYTES	317.4	Cells/cu.mm	200-1000	Calculated
BASOPHILS	26.45	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	172000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	25	mm at the end of 1 hour	0-20	Modified Westergren

RBCs ARE NORMOCYTIC NORMOCHROMIC WITH FEW MICROCYTIC HYPOCHROMIC CELLS.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Page 2 of 12





Age/Gender : 32 Y 5 M 16 D/F UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963 Collected : 27/Nov/2023 10:19AM Received : 27/Nov/2023 10:55AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 27/Nov/2023 04:07PM

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y ANNUAL PLUS C	HECK ADVANCI	ED - FEMALE - TMT - PA	AN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

Reported

BLOOD GROUP ABO AND RH FACTOR , WHOLE BLOOD EDTA				
BLOOD GROUP TYPE	В		Forward & Reverse Grouping with Slide/Tube Aggluti	
Rh TYPE	POSITIVE		Forward & Reverse Grouping with Slide/Tube Agglutination	

Page 3 of 12







Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390 Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 48963

Collected : 27/Nov/2023 12:12PM

Received : 27/Nov/2023 04:25PM Reported : 27/Nov/2023 07:13PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

GLUCOSE, FASTING, NAF PLASMA	95	mg/dL	70-100	GOD - POD	
= = -	= =	J.			

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2	82	mg/dL	70-140	GOD - POD
HOURS , SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 4 of 12









Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963 Collected : 27/Nov/2023 10:19AM

Received : 27/Nov/2023 01:16PM Reported : 27/Nov/2023 03:35PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HBA1C, GLYCATED HEMOGLOBIN,	5.2	%	HPLC
WHOLE BLOOD EDTA			
ESTIMATED AVERAGE GLUCOSE (eAG)	103	ma/dl	Calculated

Comment:

WHOLE BLOOD EDTA

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 - 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 12





Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963 Collected : 27/Nov/2023 10:19AM

Received : 27/Nov/2023 11:23AM Reported : 27/Nov/2023 07:10PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BOD	V ANNUAL DILIC CI	HECK ADVANC	ED EEMALE THE D	ANIMOIA EVOCOA
AKCOPEINII - INIEDIWHEEL - FULL BOD	T ANNUAL PLUS CI	HECK ADVANC	ED - FEMALE - IMII - PA	AN INDIA - F 1 2324
Test Name	Result	Unit	Die Def Denge	Method
rest Name	Result	Unit	Bio. Ref. Range	wethou

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	149	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	192	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	34	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	115	mg/dL	<130	Calculated
LDL CHOLESTEROL	76.6	mg/dL	<100	Calculated
VLDL CHOLESTEROL	38.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	4.38		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
III .I D1 .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- **6.** VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 12







Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963 Collected : 27/Nov/2023 10:19AM

Received : 27/Nov/2023 11:23AM Reported : 27/Nov/2023 07:10PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ADCOEEMI MEDIWHEEL EIILI BOD	V ANNIIAI DILICO	TECK VD//VNCI	ED EEMALE THE D	AN INDIA EV2224		
ARCOLEMI - MIEDIAALIEEE - LOEE BOD	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method		
	1100011	• • • • • • • • • • • • • • • • • • • •	2.01.1011.1011.90			

LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.50	mg/dL	0.20-1.20	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.30	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	20	U/L	<35	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	24.0	U/L	14-36	UV with P-5-P
ALKALINE PHOSPHATASE	73.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.40	g/dL	6.3-8.2	Biuret
ALBUMIN	4.20	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.20	g/dL	2.0-3.5	Calculated
A/G RATIO	1.31		0.9-2.0	Calculated

Comment:

 $LFT\ results\ reflect\ different\ aspects\ of\ the\ health\ of\ the\ liver,\ i.e.,\ hepatocyte\ integrity\ (AST\ \&\ ALT),\ synthesis\ and\ secretion\ of\ bile\ (Bilirubin,\ ALP),\ cholestasis\ (ALP,\ GGT),\ protein\ synthesis\ (Albumin)$

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- \bullet ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- $\bullet \ To \ establish \ the \ hepatic \ origin \ correlation \ with \ GGT \ helps. \ If \ GGT \ elevated \ indicates \ hepatic \ cause \ of \ increased \ ALP.$

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.





Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963 Collected : 27/Nov/2023 10:19AM

Received : 27/Nov/2023 11:23AM Reported : 27/Nov/2023 07:10PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324					
ARCOFEMI - MEDIWHEEL - FULL BODT ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - F12524					
Test Name Result Unit Bio, Ref. Range Method					
rest name	Result	Unit	Bio. Ref. Range	wiethou	

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM						
CREATININE	0.50	mg/dL	0.5-1.04	Creatinine amidohydrolase		
UREA	30.00	mg/dL	15-36	Urease		
BLOOD UREA NITROGEN	14.0	mg/dL	8.0 - 23.0	Calculated		
URIC ACID	5.30	mg/dL	2.5-6.2	Uricase		
CALCIUM	8.40	mg/dL	8.4 - 10.2	Arsenazo-III		
PHOSPHORUS, INORGANIC	3.50	mg/dL	2.5-4.5	PMA Phenol		
SODIUM	136	mmol/L	135-145	Direct ISE		
POTASSIUM	4.2	mmol/L	3.5-5.1	Direct ISE		
CHLORIDE	102	mmol/L	98 - 107	Direct ISE		

Page 8 of 12







Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439 Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963 Collected : 27/Nov/2023 10:19AM Received : 27/Nov/2023 11:23AM

Reported : 27/Nov/2023 04:20PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y ANNUAL PLUS C	HECK ADVANC	ED - FEMALE - TMT - P.	AN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GAMMA GLUTAMYL TRANSPEPTIDASE	13.00	U/L	12-43	Glyclyclycine
(GGT), SERUM				Nitoranalide

Page 9 of 12





Ref Doctor



Patient Name : Mrs.RUPAL KUMARI

Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439

: Dr.SELF

Visit ID : SCHIOPV23390

Emp/Auth/TPA ID : 48963

Collected : 27/Nov/2023 10:19AM

Received : 27/Nov/2023 06:36PM

Reported : 27/Nov/2023 09:02PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method						

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	0.94	ng/mL	0.7-2.04	CLIA		
THYROXINE (T4, TOTAL) 6.52 μg/dL 5.48-14.28 CLIA						
THYROID STIMULATING HORMONE (TSH)	5.044	μIU/mL	0.34-5.60	CLIA		

Comment:

Hor pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	Т4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 10 of 12







Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963 Collected : 27/Nov/2023 10:19AM Received : 27/Nov/2023 12:23PM

Received : 27/Nov/2023 12:23PM Reported : 27/Nov/2023 12:46PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

COMPLETE URINE EXAMINATION (CUE)	, URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	5.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.015		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION			•	
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MOUNT	AND MICROSCOPY	•		
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 11 of 12







Age/Gender : 32 Y 5 M 16 D/F

UHID/MR No : SCHI.0000016439

Visit ID : SCHIOPV23390

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 48963 Collected : 27/Nov/2023 10:19AM Received : 27/Nov/2023 12:23PM

Reported : 27/Nov/2023 12:46PM

Status : Final Report
Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y ANNUAL PLUS CI	HECK ADVANCI	ED - FEMALE - TMT - PA	AN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

LIDINE OLLIGOOF/EACTING)	NICOATIVE	NIEGATIVE	D: (: 1	
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE	Dipstick	

URINE GLUCOSE(FASTING) NEGATIVE

NEGATIVE [

Dipstick

*** End Of Report ***

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Lovekesh Monga M.B.B.S,M.D(Pathology) Consultant Pathologist. Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

Page 12 of 12







Name : Mrs. Rupal Kumari

Plan

Age: 32 Y

UHID:SCHI.0000016439

Sex: F

Address: prahladpue new delhi
: ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN

OP Number: SCHIOPV23390 Bill No : SCHI-OCR-8692

INDIA OP AGREEMENT

Date : 27.11.2023 10:09

no	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE	- TMT - PAN INDIA - FY2324
	URINE GLUCOSE(FASTING)	
	GAMMA GLUTAMYL TRANFERASE (GGT)	
	SONO MAMOGRAPHY - SCREENING	
	HbA1c, GLYCATED HEMOGLOBIN	
	LIVER FUNCTION TEST (LFT)	
(X-RAY CHEST PA	
- 1	7 GLUCOSE, FASTING	
8	HEMOGRAM + PERIPHERAL SMEAR	
9	ENT CONSULTATION	
10	CARDIAC STRESS TEST(TMT)	
1	FITNESS BY GENERAL PHYSICIAN	
12	2 GYNAECOLOGY CONSULTATION	
13	DIET CONSULTATION	
14	COMPLETE URINE EXAMINATION	
15	URINE GLUCOSE(POST PRANDIAL) .	
10	PERIPHERAL SMEAR	
17	ECG /	
18	BLOOD GROUP ABO AND RH FACTOR	
19	LIPID PROFILE	
20	BODY MASS INDEX (BMI)	
21	LBC PAP TEST- PAPSURE / not close > (penders)	
22	OPTHAL BY GENERAL PHYSICIAN 4 🗸	
23	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
	ULTRASOUND - WHOLE ABDOMEN 9	
	THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	
	DENTAL CONSULTATION V	
27	GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)	

Mb 9.6

Height:		164
Weight:	1999A	55.1
B.P:	110/7)
Pulse:		6

Spoz-99

FO Desk

From:

noreply@apolloclinics.info

Sent:

03 November 2023 12:26

To: Cc: rupaldovebird@gmail.com phc.klc@apollospectra.com; syamsunder.m@apollohl.com;

cc.klc@apollospectra.com

Subject:

Your Apollo order has been confirmed



Dear MS. KUMARI RUPAL .,

Namaste Team,

Greetings from Apollo Clinics,

With regards to the below request the below appointment is scheduled at **SPECTRA NEHRU ENCLAVE** clinic on 2023-11-25 at 09:25-09:30.

Payment Mode	Credit
Corporate Name	ARCOFEMI HEALTHCARE LIMITED
Agreement Name	ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN INDIA OP AGREEMENT
Package Name	[ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324]

[&]quot;As stated in the agreement terms, kindly carry all relevant documents such as HR Authorization Letter, Appointment Confirmation Mail, valid government ID proof, company ID card etc. along with you."

Note: Video recording or taking photos inside the clinic premises or during camps is not allowed and would attract legal consequences.

Note: Also once appointment is booked, based on availability of doctors at clinics tests will happen, any pending test will happen based on doctor availability and clinics will be updating the same to customers.





DIGITAL X-RAY REPORT

NAME: RUPAL	DATE: 27.11.2023
UHID NO: 16439	AGE: 32YRS/ SEX: F

X-RAY CHEST PA VIEW

Both the lung fields show no active parenchymal pathology.

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab investigations

DR. MONICA CHHABRA Consultant Radiologist

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744

Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Dr. Lalit Mohan Parashar

MS (ENT)
Ear, Nose, Throat Specialist and
Head & Neck Surgeon

For Appointment : +91 11 40465555 Mob.; +91 9910995018 MCI No. 4774/85 RUPM RUMMI



32/5

To PRODUNCE MORNING CUICA NO LEADING TONG COMPLAINTS Whose - STORM MIDLING

THRONT- NAS

Ess - Be TM Norma

VOICE, SPIZZIA MIS NELLINE (N)

FNT- NORMAL

27/11/2023

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.

24/11/23

18- Rope Kuman



32/2

Adrigation

UCIDIO WOUT

Afar hora

8/160

B the across

In an

Somelle Ege Dop

dall

Dr Hle

(of our

parden- wer (DE)

= Ce/c

0 0

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.



27/11/2023.

Mers. Rupal Kumari., 32 Years / Fernali.,

Act Regular Denta Check up,

M/HI- N-R-

PDH L. N.R.

O/E!-. Calculus ++1 Stains peusent.

Admisod: Scaling of Olal Ruophylamins (")

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

LMP-25/11/23

Apollo Spectra

HOSPITALS

Specialists in Surgery

on periled

PH - mi

ML - ly

FM-M

0/e-90 Jain

PARAM

brearts - 19/1-

Rupal Kumani 32/1=. 27/11/23 Bhe.


Adv

T. MCBM 69 0D _ · — (3 mm prior conception)

drowin)

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.





NAME:	RUPAL KUMARI	AGE/SEX:	32	YRS./F
UHID:	16439			
REF BY:	APOLLO SPECTRA	DATE:-	27.11	.2023

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and echotexture. Intrahepatic biliary radicles are not dilated. No focal or diffuse lesion is seen. CBD and portal vein are normal in caliber.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Uterus is antiverted and normal in size. It measures 7.8 x 3.6 cm. Outline is smooth. Myometrium is normal. Endometrial echoes are normal and measures 4.7 mm

Both ovaries are normal in size, shape and echotexture.

Right ovary: 3.3 x 1.8 cm **Left ovary:** 2.8 x 2 cm

No obvious adenexal mass is seen. No free fluid seen.

IMPRESSION: NO SIGNIFICANT ABNORMALITY.

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRACONSULTANT RADIOLOGIST

Dr. MONICA CHHABRA
Consultant Radiologist
DMC No. 18744
Apollo Spectra Hospitals
New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



Name:	RUPAL KUMARI	Age/Sex	32	Yrs. /F
UHID:	16439		1	,.
Ref By:	APOLLO SPECTRA	Date:-	27.11	.2023

USG BOTH BREAST

Both breast shows normal parenchymal pattern.

No obvious architectural distortion seen.

No abnormal ductal dilatation seen.

Skin and subcutaneous tissues are normal.

No abnormal vascularity seen on both sides.

Bilateral subareolar regions are unremarkable.

Few small axillary nodes with preserved fatty hilum are seen bilaterally.

IMPRESSION: USG breast reveals:

No significant abnormality

Advise: Clinical Correlation.

DR'. MONICA CHHABRACONSULTANT RADIOLOGIST

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



Patient Name

: Mrs. Rupal Kumarı

UHID Conducted By: : SCHI.0000016439 : Dr. MUKESH K GUPTA

Referred By

: SELF

Age

OP Visit No Conducted Date 32 Y/F

SCHIOPV23390

27-11-2023 16:05

Protocol

Bruce Protocol

Medication Target Heart Rate

188 BPM 179 BPM

Heart Rate Achieved Percentage of THR Achieved

95% 128/86 mm

Maximum Blood Pressure Total Exercise Duration Maximum Worked Attained Reason for termination 128/86 mmHg 06:06 Min. 07.10 Mets Max HR Attained.

Comments

- Basal ECG NSR.
- Appropriate HR response.
- Appropriate BP response.
- · No significant changes with standing and hyperventilation.
- Good exercise tolerance.
- No significant ST segment depression over baseline during exercise or recovery period.
- No crepts or rhonchi.
- Arrhythmia none.
- Chest pain absent.

Summary

- Test is negative for provocable myocardial ischemia.
- Good exercise tolerance.
- Appropriate BP response.

Please correlate clinically Not valid for medico legal purpose.



Dr. M K Gupta M.B.B.S, MD,FIACM Senior Consultant Cardiologist

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.

				RECOVERY			FXFRCISE			PRETEST	I lasc ivalic	Dhace Name														md67:70:1	27.11.2023	Patient ID: 16349
					STAGE 3	STAGE 2	STAGE 1	HYPERV.	STANDING	SUPINE	0.000	Stage Name									Ρ.	Ref. MD: Ord	Medical History.	Test Reason:	Ivious.	Meds.	Female 164 cm	
				03:09	00:07	03:00	03:00	00:05	00:52	02:13	in Stage	Time								,	Test Type:	Ordering MD:					55.1 kg	
				0.00	2.90	2.50	1.70	0.00	0.00	0.00	[mph]	Speed																
				0.00	13.60	12.00	10.00	0.00	0.00	0.00	[%]																	
					7.1		4.6				[METS] [b																	
				96 1207/0		166 128/86	162 110/70	∞ 0	×, <u>~</u>	88 110/70	u] [u	HR BP	Location	Room:	- appro	Summ	Reasor	QRS di	ST/HR	II R rec	HR res	ST/HR	ST/HR	Amhyd	Maxim	Max BI	Max Hi	28 TO
				07.01.1				8910	0170] [mmHg*bp [/min]	RPP	ocation: * 0 *		-appropriate response. Chest Pain: none	ary:	Reasons for Termination: Max HR attained	QRS duration: BASELINE: 80 ms, PEAK EX:	ST/HR hysteresis: 0.019 mV (II)	HR recovery: 29 bpm	HR reserve used: //%	slope: 1.50 μ	ST/HR index: 2.36 µV/bpm	Max. S1:-1:80 IIIII, -0:54 III V/S III II, III Arrhythmia: A:75. VBIG:1. PVC:17,	Maximum Workload: 7.10 METS	2: 128/86 mm	2: 179 bpm 9	RHCF: Exercise Time 06:06
				c	00	0		0 (00	-					e. Chest Pai	or oppro-	ation: Max I	ELINE: 80 ms)19 mV (II)		%	V/bpm (II)	V/bpm	/BIG:1. PV(7.10 METS	dg BP at res	15 % of max p	ne 06:06
				0.50	- - 1.80	-1.45	-0.95	0.00	0.00	0.00	II [mm]	STLevel C			n: none.	rigte RP Re	R attained	, PEAK EX:						H, ESTC:3	II. EXERCIO	t: 110/70 N	redicted 188	
												Comment			opolio de	Summary: BP Recogne to Exercise: normal resting BP		72 ms, REC:						Max. S1:-1.80 IIIII, -0.74 IIIV/S III II, EXEXCED STREET S	E STACE 3	Max BP: 128/86 mmHg BP at rest: 110/70 Max RPP: 22912 mmHg*bpm	Max HR: 179 bpm 95 % of max predicted 188 bpm HR at rest: 70	
																orcise.		80 ms							6-07)12 mi	est: 7	
																norma										nHg*bp	0	

GE CardioSoft V7.0 (10) Unconfirmed Attending MD:

Page 1